Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Ever since the significance of pathological 43-kDa transactivating responsive sequence DNA-binding protein (TDP-43) for human disease has been recognized in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin positive inclusions (FTLD-U), a number of publications have emerged reporting on this pathology in a variety of neurodegenerative diseases. Given the heterogeneous and, in part, conflicting nature of the recent findings, we here review pathological TDP-43 and its relationship to human disease with a special focus on ALS and FTLD-U. To this end, we propose a classification scheme in which pathological TDP-43 is the major disease defining pathology in one group, or is present in addition to other neurodegenerative hallmark pathologies in a second category. We conclude that the TDP-43 proteinopathies represent a novel class of neurodegenerative disorders akin to α-synucleinopathies and tauopathies, with the concept of ALS and FTLD-U to be widened to a broad clinico-pathological multisystem disease, i.e., TDP-43 proteinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 4×
“The idea of a predominantly frontotemporal degeneration pattern in FTLD-U and a primarily pyramidal tract degeneration pattern in MND should be refined in favor of a broad clinico-pathological spectrum disorder involving multiple systems with differences being present at group level, but not necessarily in a given cas…”
BackgroundInfluentialSelf-citationArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 1×
“Recent findings of mutations in the TARDP gene in cases of familial autosomal dominant and rare sporadic ALS patients further corroborate the significance of pathological TPD-43 as being mechanistically implicated in the disease process [9, 22, 35, 36, 39, 50, 52, 84, 91, 101, 108].”
ResultMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 1×
“Recent findings of mutations in the TARDP gene in cases of familial autosomal dominant and rare sporadic ALS patients further corroborate the significance of pathological TPD-43 as being mechanistically implicated in the disease process [9, 22, 35, 36, 39, 50, 52, 84, 91, 101, 108].”
ResultCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 1×
“PGRN gene mutations cause TDP-43 pathology which is restricted to subtype 3 [8, 18, 19, 21, 90].”
BackgroundCairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · cited 5×
“associated recommended neuropathological nomenclature, including the morphological subtypes, have been the subject of detailed reviews [10, 18, 24, 54, 55, 63, 73].”
BackgroundResultInfluentialSelf-citationMackenzie, I. R. A., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., Kwong, L. K., Forman, M. S., Ravits, J., Stewart, H., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21147 · Cited by 992 · cited 2×
“degeneration in these apparently similar entities may result from different mechanisms [60].”
BackgroundSelf-citationTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“Thus, it was shown that TDP-43 pathology is present predominantly in the medial temporal lobe limbic structures in a number of cases of Alzheimer’s disease and hippocampal sclerosis [2–4, 19, 44, 45, 100].”
BackgroundMutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hummerich, H., Nielsen, J. E., Hodges, J. R., Spillantini, M. G., Thusgaard, T., et al. (2005) · Nature Genetics · doi:10.1038/ng1609 · Cited by 822 · cited 1×
“Additionally, there are other rare TDP-43 negative entities, such as FTD linked to chromosome 3 due to mutations in the charged multivesicular body protein 2B gene [18, 89].”
BackgroundPhosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21425 · Cited by 777 · cited 4×
“Ultrastructurally, several studies focusing on the TDP-43 inclusions showed granular and filamentous material (with an average width of ∼15 nm) that labeled for TDP-43 to a variable degree [41,57,69,76,77,99].”
BackgroundResultInfluentialVan Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70071-1 · Cited by 723
Self-citationThe central nervous system in motor neurone disease
Brownell, B., Oppenheimer, D. R., & Hughes, J. T. (1970) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.33.3.338 · Cited by 483
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0261-2 · Cited by 468 · cited 2×
“For the a-synucleinopathies—Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies—concomitant TDP-43 pathology has been reported [4, 44, 57, 71].”
BackgroundSelf-citationUryu, K., Nakashima-Yasuda, H., Forman, M. S., Kwong, L. K., Clark, C. M., Grossman, M., Miller, B. L., Kretzschmar, H. A., Lee, V. M.-Y., Trojanowski, J. Q., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817713b5 · Cited by 382 · cited 2×
“The data on the TDP-43 immunoreactivity of Pick’s bodies in Pick’s disease are conflicting, but TDP-43 pathology is uncommon in this disorder and not yet verified by western blot analysis [3, 29, 43, 44, 57, 100].”
BackgroundSelf-citationTDP ‐ 43 mutation in familial amyotrophic lateral sclerosis
Yokoseki, A., Shiga, A., Tan, C., Tagawa, A., Kaneko, H., Koyama, A., Eguchi, H., Tsujino, A., Ikeuchi, T., Kakita, A., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21392 · Cited by 373 · cited 1×
“Recent findings of mutations in the TARDP gene in cases of familial autosomal dominant and rare sporadic ALS patients further corroborate the significance of pathological TPD-43 as being mechanistically implicated in the disease process [9, 22, 35, 36, 39, 50, 52, 84, 91, 101, 108].”
ResultPhosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies
Arai, T., Mackenzie, I. R. A., Hasegawa, M., Nonoka, T., Niizato, K., Tsuchiya, K., Iritani, S., Onaya, M., & Akiyama, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0480-1 · Cited by 345
Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies
Geser, F., Martinez-Lage, M., Robinson, J., Uryu, K., Neumann, M., Brandmeir, N. J., Xie, S. X., Kwong, L. K., Elman, L., McCluskey, L., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.558 · Cited by 267 · cited 6×
“We demonstrated that all the clinical groups showed widespread CNS TDP-43 pathology; however, the presence of MND was associated with a higher burden of inclusions in lower motor neurons [32].”
BackgroundInfluentialSelf-citationIncreased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Kasai, T., Tokuda, T., Ishigami, N., Sasayama, H., Foulds, P., Mitchell, D. J., Mann, D. M. A., Allsop, D., & Nakagawa, M. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0456-1 · Cited by 211 · cited 1×
“Recent studies reporting on elevated TDP-43 plasma levels in clinically diagnosed FTD (and AD) and increased cerebrospinal fluid TDP-43 levels in FTLD-U and ALS patients as compared with controls are intriguing, as they might offer a diagnostic ante-mortem tool and a biomarker for interventional clinical trials, but t…”
BackgroundSteinacker, P., Hendrich, C., Sperfeld, A. D., Jesse, S., von Arnim, C. A. F., Lehnert, S., Pabst, A., Uttner, I., Tumani, H., Lee, V. M.-Y., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1481 · Cited by 199
Self-citationNishihira, Y., Tan, C.-F., Onodera, O., Toyoshima, Y., Yamada, M., Morita, T., Nishizawa, M., Kakita, A., & Takahashi, H. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0385-z · Cited by 187 · cited 4×
“In fact, the distribution of the pathology in ALS with/without dementia has been split into two different types by cluster analysis with one of them being the more severe and FTLD-U-like ‘‘dementia’’ morphological type involving the hippocampal formation, neocortex and basal ganglia, and the other one being more restr…”
BackgroundInfluentialProgranulin genetic variability contributes to amyotrophic lateral sclerosis
Sleegers, K., Brouwers, N., Maurer-Stroh, S., van Es, M. A., Damme, P. V., van Vught, P. W. J., van der Zee, J., Serneels, S., Pooter, T. D., Van den Broeck, M., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000289191.54852.75 · Cited by 161
Overlap between neurodegenerative disorders
Armstrong, R. A., Lantos, P. L., & Cairns, N. J. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00605.x · Cited by 146 · cited 1×
“The recognition of TDP-43 proteinopathies as a new class of neurodegenerative disorder has raised the question as to the existence of this pathology in other disorders, since it is known that neurodegenerative diseases frequently exhibit overlapping morphological features (for review see [5]).”
BackgroundChen-Plotkin, A. S., Geser, F., Plotkin, J. B., Clark, C. M., Kwong, L. K., Yuan, W., Grossman, M., Van Deerlin, V. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn023 · Cited by 135 · cited 1×
“Despite the lack of apparent clinical or neuropathological differences between cases with and without PGRN gene abnormalities, a distinct phenotype appears to be present at the molecular level [20].”
BackgroundSelf-citationMishra, M., Paunesku, T., Woloschak, G. E., Siddique, T., Zhu, L., Lin, S., Greco, K., & Bigio, E. H. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0240-7 · Cited by 95
Cited by
Chronic neuropathologies of single and repetitive TBI: substrates of dementia?
Smith, D. H., Johnson, V. E., & Stewart, W. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.29 · Cited by 699
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy
McKee, A. C., Gavett, B. E., Stern, R. A., Nowinski, C. J., Cantu, R. C., Kowall, N. W., Perl, D. P., Hedley-Whyte, E. T., Price, B., Sullivan, C., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ee7d85 · Cited by 659
“The FTLD-TDP, FTLD-MND/ ALS-D, and ALS all show widespread CNS TDP-43 pathology; however, the presence of MND or ALS is associated with a higher burden of inclusions in lower motor neurons, and cognitive dysfunction is related to a higher degree of cortical pathology (6, 62).”
BackgroundThe bowel and beyond: The enteric nervous system in neurological disorders
Rao, M., & Gershon, M. D. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.107 · Cited by 629
Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V., Ceuterick-de Groote, C., Van Broeckhoven, C., & Kumar-Singh, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912417107 · Cited by 587
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
“The syndromes classified under frontotemporal lobar egeneration (FTLD) manifest initially with three major ypes of clinical deficits before progressing to full dementia. hese can be roughly classified into deficits of behavioral nhibition/control (e.g., Pick’s disease) and language abnoralities (e.g., primary progress…”
Influential
Metadata
- Authors
- Geser, F., Martinez-Lage, M., Kwong, L. K., Lee, V. M.-Y., & Trojanowski, J. Q.
- Venue
- Journal of Neurology
- Published
- 2009-03-07
- Volume
- 256
- Issue
- 8
- Pages
- 1205-1214
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2045189928
- Cited by
- 194
- References
- 25
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.